Peripheral Arterial Disease (PAD)/ Peripheral Vascular

Disease (PVD) - Pipeline Review, H2 2015 Is Released

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015
Summary Global Markets Direct s, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Review, H2 2015, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral
Vascular Disease (PVD)s therapeutic pipeline. This report provides comprehensive information on the
therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),
complete with comparative analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players involved in the therapeutic
development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special
features on late-stage and discontinued projects. Global Markets Directs report features investigational
drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases,
Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets
Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a
stringent set of processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking, browser based alert-box and
clinical trials registries tracking ensure that the most recent developments are captured on a real time
basis. The report enhances decision making capabilities and help to create effective counter strategies
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data for the indicated disease. Scope - The report
provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral
Vascular Disease (PVD) - The report reviews key pipeline products under drug profile section which
includes, product description, MoA and R&D brief, licensing and collaboration details & other
developmental activities - The report reviews key players involved in the therapeutics development for
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and
minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of
the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development
by companies and universities/research institutes based on information derived from company and
industry-specific sources - Pipeline products coverage based on various stages of development ranging
from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and
combination therapy pipeline projects - Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral
Vascular Disease (PVD) pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically
significant competitor information, analysis, and insights to formulate effective R&D development
strategies - Identify emerging players with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the
focus areas of leading companies - Identify and understand important and diverse types of therapeutics
under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Plan
1

mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise
corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral
Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics - Develop and design inlicensing and out-licensing strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by
identifying discontinued projects and understanding the factors that drove them from pipeline.
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173374/peripheralarterial-disease-pad-peripheral-vascular-disease-pvd-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173374/peripheral-arterial-disease-pad-peripheral-vascular-disease-pvd-pipeline-reviewh2-2015

Table of Contents

Introduction 9
Global Markets Direct Report Coverage 9
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10
Therapeutics Development 11
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 11
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development
by Companies 12
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by
Companies 18
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in
Therapeutics Development 21
Alvogen Korea 21
AnGes MG, Inc. 22
AstraZeneca Plc 23
2

Athersys, Inc. 24
Bayer AG 25
Betagenon AB 26
Cardiolynx AG 27
CardioVascular BioTherapeutics, Inc. 28
Celgene Corporation 29
Diffusion Pharmaceuticals LLC 30
DNAVEC Corporation 31
Hemostemix Ltd 32
Mesoblast Limited 33
miRagen Therapeutics, Inc. 34
Multi Gene Vascular Systems Ltd 35
Nuo Therapeutics, Inc. 36
Proteon Therapeutics, Inc. 37
Recardio GmbH 38
Resverlogix Corp. 39
Sagene Pharmaceuticals, Inc. 40
Stemedica Cell Technologies, Inc. 41
Symic Biomedical, Inc. 42
Theravasc, Inc. 43
ViroMed Co., Ltd. 44
Yuyu Pharma, Inc. 45
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
(cilostazol + organic nitrate) ER - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ACP-01 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AEM-28 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ALD-301 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Annexin A-5 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
apabetalone - Drug Profile 64
Product Description 64
Mechanism of Action 64
4

R&D Progress 64
beperminogene perplasmid - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CVBT-141C - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DVC1-0101 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ELS-140 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MGN-6114 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
MultiGeneAngio - Drug Profile 78

Product Description 78
Mechanism of Action 78
R&D Progress 78
MultiStem - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
O-304 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
PDA-002 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
REC-03 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Rejuveinix - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
rivaroxaban - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
6

sarpogrelate SR - Drug Profile 95

Product Description 95
Mechanism of Action 95
R&D Progress 95
SB-030 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
selegiline + Antiplatelet Drugs - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
sodium nitrite SR - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease,
Infectious Disease and Toxicology - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Synthetic Peptide to Inhibit PAI-1 for Cardiovascular Diseases and Oncology - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
ticagrelor - Drug Profile 103
Product Description 103
7

Mechanism of Action 103

R&D Progress 103
transcrocetinate sodium - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
TXA-127 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
VM-202 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
vonapanitase - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
YY-984 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates 115
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 160
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 162
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
163
8

Featured News & Press Releases 163

Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug
Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 163
Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational
Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease 163
Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 164
Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon
Therapeutics' PRT-201 in Peripheral Artery Disease 165
Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and
Biomarker Efficacy Signals 165
Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with
BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of
Cardiology Scientific Session 166
Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 168
Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease
169
Oct 15, 2012: Proteon Therapeutics Initiates Patient Enrollment In Phase I Clinical Study Of PRT-201 In
Patients Suffering From Peripheral Artery Disease 170
Aug 17, 2012: Anges Announces Publication of Long-Term Phase I/II Trial Data of Collategene In Medical
Journal 170
Appendix 171
Methodology 171
Coverage 171
Secondary Research 171
Primary Research 171
Expert Panel Validation 171
Contact Us 171
Disclaimer 172

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173374/peripheral-arterialdisease-pad-peripheral-vascular-disease-pvd-pipeline-review-h2-2015
About Us:
9

iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects

10

11